SUPN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc.
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. for potential securities fraud violations. This follows the company's announcement that its Phase 2b study of SPN-820 for treatment-resistant depression did not meet its primary endpoint.
February 19, 2025 | 7:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Supernus Pharmaceuticals faces an investigation by Levi & Korsinsky for potential securities fraud after its Phase 2b study of SPN-820 failed to meet primary endpoints.
The failure of the SPN-820 study is a significant setback for Supernus Pharmaceuticals, potentially affecting investor confidence and leading to legal challenges. The investigation by Levi & Korsinsky could further impact the company's stock negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100